Vol. 7, Issue 2, Part A (2025)

Background: Cardiovascular aging is driven by endothelial senescence, mitochondrial dysfunction, and metabolic inflexibility. Although both SIRT1 and AMPK individually protect against vascular aging, no current therapy provides simultaneous, synergistic activation of both pathways.

Objective: To propose and mechanistically define a novel compound, SIRAMP-21, engineered as a hybrid molecule combining E-guggulsterone (a SIRT1-enhancing FXR antagonist) and methyl-chlorogenate (MCG; an AMPK activator) to achieve dual pathway activation for vascular rejuvenation.

Methods: A mechanistic systems-biology analysis integrating molecular docking evidence, biochemical literature, and metabolic pharmacology was used to develop the SIRAMP-21 interaction model. Chemical synthesis logic, pharmacokinetic predictions, and molecular-pathway convergence were mapped to endothelial aging hallmarks.

Results: Theoretical mapping revealed:

• E-guggulsterone indirectly enhances SIRT1 by suppressing FXR → ↑ bile-acid turnover → ↑ NAD⁺ availability → ↑ SIRT1 activity.
• MCG allosterically activates AMPK via γ-subunit binding, improving mitochondrial bioenergetics.
• Combined SIRT1-AMPK activation forms a positive feedback loop enhancing PGC-1α, eNOS, mitochondrial biogenesis, autophagy, and anti-inflammatory gene expression.
• Structural hybridization improves lipophilicity, oral bioavailability, and geriatric pharmacokinetics.

Conclusion: SIRAMP-21 represents the first theoretically rationalized compound designed to synchronously activate SIRT1 and AMPK, offering a paradigm shift from disease management toward engineering cardiovascular longevity.